1167 Novel Medications to Optimize Sleep in Neurodevelopmental Disorders
Abstract
Sleep initiation and maintenance difficulties are highly prevalent in individuals with neurodevelopmental disorders (NDDs) and contribute to impaired daytime functioning, behavioral dysregulation, caregiver sleep loss, and reduced quality of life. Sleep disruption may exacerbate neurobiological dysfunction through alteration of neurotransmitter systems and inflammatory pathways. Despite the clinical significance, commonly used sleep agents-such as melatonin, clonidine, gabapentin, and trazodone- are often ineffective in this population, and evidence supporting newer sleep medications in NDDs remains sparse.
A prospective evaluation was conducted for 2 clinic patients with documented NDDs and chronic sleep impairment who were treated with newer sleep-targeting therapies. The Children’s Sleep Habits Questionnaire (CSHQ) was used to quantify changes in sleep quality.
Case 1: A 24-year-old male with Dravet syndrome (SCN1A mutation) developed profound insomnia following an ICU hospitalization requiring dexmedetomidine. He slept only 4 hours nightly, with frequent awakenings that required constant parental monitoring. Trials of melatonin and zolpidem were ineffective. Initiation of daridorexant 50 mg nightly resulted in near-complete resolution of nocturnal awakenings and increased sleep to 10 hours nightly. His CSHQ score improved from 75 to 34, allowing parents to resume typical nighttime routines. After 3 months, he developed night terrors and the medication was tapered. Case…
Read the paper
Related studies
- Tryptophan Metabolism and Gut-Brain Homeostasis
- Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer’s Disease and MCI: A Review
- Prioritized Research for the Prevention, Treatment, and Reversal of Chronic Disease: Recommendations From the Lifestyle Medicine Research Summit
- Relationship between sleep disorders and gut dysbiosis: what affects what?
- The role of CLOCK gene in psychiatric disorders: Evidence from human and animal research
- Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer’s Disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.